3-(5-bromo-4-methoxyimidazo[5,1-f][1,2,4]triazin-7-yl)cyclobutanone | 1196394-35-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-(5-bromo-4-methoxyimidazo[5,1-f][1,2,4]triazin-7-yl)cyclobutanone
• 英文别名: 3-(5-Bromo-4-methoxy-imidazo[5,1-f][1,2,4]triazin-7-yl)-cyclobutanone；3-(5-bromo-4-methoxyimidazo[5,1-f][1,2,4]triazin-7-yl)cyclobutan-1-one
• CAS: 1196394-35-0
• 化学式: C₁₀H₉BrN₄O₂
• 分子量: 297.111
• InChiKey: XMOYLQMPNYXSAF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  69.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(5-bromo-4-methoxyimidazo[5,1-f][1,2,4]triazin-7-yl)cyclobutanone 在 氨 作用下， 以 异丙醇 为溶剂， 生成
  参考文献：
  名称：

  Discovery of an Orally Efficacious Imidazo[5,1-f][1,2,4]triazine Dual Inhibitor of IGF-1R and IR

  摘要：

  This report describes the investigation of a series of 5,7-disubstituted imidazo[5,1-f][1,2,4]triazine inhibitors of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR). Structure-activity relationship exploration and optimization leading to the identification, characterization, and pharmacological activity of compound 9b, a potent, selective, well-tolerated, and orally bioavailable dual inhibitor of IGF-1R and IR with in vivo efficacy in tumor xenograft models, is discussed.

  DOI：

  10.1021/ml100178g
• 作为产物：
  描述：

  3-oxocyclobutanecarboxylic acid 2,5-dioxopyrrolidin-1-yl ester 在 N-溴代丁二酰亚胺(NBS) 、 碳酸氢钠 、 三氯氧磷 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成 3-(5-bromo-4-methoxyimidazo[5,1-f][1,2,4]triazin-7-yl)cyclobutanone
  参考文献：
  名称：

  Discovery of an Orally Efficacious Imidazo[5,1-f][1,2,4]triazine Dual Inhibitor of IGF-1R and IR

  摘要：

  This report describes the investigation of a series of 5,7-disubstituted imidazo[5,1-f][1,2,4]triazine inhibitors of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR). Structure-activity relationship exploration and optimization leading to the identification, characterization, and pharmacological activity of compound 9b, a potent, selective, well-tolerated, and orally bioavailable dual inhibitor of IGF-1R and IR with in vivo efficacy in tumor xenograft models, is discussed.

  DOI：

  10.1021/ml100178g

文献信息

• SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES
  申请人：Crew Andrew P.

  公开号：US20090286768A1

  公开（公告）日：2009-11-19

  Fused pyridine-based bicyclic compounds having the structure of Formula I, as defined herein, pharmaceutically acceptable salts thereof, preparation, compositions, and disease treatment therewith. This abstract does not define or limit the invention.

  基于融合吡啶的双环化合物具有如下所定义的结构，其药学上可接受的盐，制备方法，组合物及其用于疾病治疗。本摘要不定义或限制该发明。
• [EN] DEUTERATED TYROSINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE TYROSINE KINASE DEUTÉRÉS
  申请人：OSI PHARM INC

  公开号：WO2011060112A1

  公开（公告）日：2011-05-19

  Compounds of Formula I, as shown below and defined herein: enriched in deuterium, and pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by IGF-1 R and/or IR.

  以下公式I的化合物，其定义如下：富含氘的化合物，以及其药学上可接受的盐，合成，中间体，配方和治疗相关疾病的方法，包括至少部分通过IGF-1 R和/或IR介导的癌症。
• Deuterated Tyrosine Kinase Inhibitors
  申请人：Epstein David M.

  公开号：US20120220595A1

  公开（公告）日：2012-08-30

  Compounds of Formula I, as shown below and defined herein: enriched in deuterium, and pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including cancers mediated at least in part by IGF-1R and/or IR.

  以下式I的化合物，其定义如下：富含氘，以及其药学上可接受的盐，合成方法，中间体，制剂，以及用于治疗疾病的方法，包括至少部分由IGF-1R和/或IR介导的癌症。
• Substituted imidazopyr- and imidazotri-azines
  申请人：Crew Andrew P.

  公开号：US08481733B2

  公开（公告）日：2013-07-09

  Fused pyridine-based bicyclic compounds having the structure of Formula I, as defined herein, pharmaceutically acceptable salts thereof, preparation, compositions, and disease treatment therewith. This abstract does not define or limit the invention.

  具有以下公式结构的融合吡啶基双环化合物，其药学上可接受的盐，制备方法，组合物以及用于疾病治疗的方法。本摘要不定义或限制发明。
• SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES
  申请人：OSI Pharmaceuticals, Inc.

  公开号：EP2283020B1

  公开（公告）日：2012-10-31